Coronavirus: Oxford/AstraZeneca Phase 1/2 trial shows safe, immunogenic vaccine, S&P 500 positive

Yohay Elam FXStreet

The Lancet published the results of the University of Oxford's Phase 1/2 in a vaccine trial. The editor of the highly regarded medical publication has tweeted that the vaccine is safe, well-tolerated, and immunogenic.

The research is done in collaboration with AstraZeneca and the UK secured around 90 million doses of the candidate, ahead of a broader trial. Apart from creating antibodies, it also triggers the creation of T-cells. This development was previously described as "double-protection."

-- more to come

The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging. https://t.co/oQp2eoZYIg
— richard horton (@richardhorton1) July 20, 2020

Administering the vaccine candidate triggered antibody responses in 32/35 (91%) participants after a single dose. After a booster dose, all participants had neutralizing activity.

The S&P 500 has turned positive after kicking off marginally lower at the beginning of a new trading week. Moderna and Pfizer/NioNTech.

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

EUR/USD trims gains, reclaims 1.1600 and beyond

Following an earlier drop to yearly lows around 1.1530, EUR/USD now manages to recoup part of the ground lost and reclaim the area above 1.1600 the figure in the latter part of the NA session on Tuesday. Meanwhile, the pair’s marked retracement comes in response to the unabate march norht in the US Dollar, always propped up by the intense flight-to-safety environment amid the deteriorating geopolitical landscape in the Middle East.

GBP/USD attacks 1.3300, refreshing three-month lows

GBP/USD is deep in the red near 1.3300, accelerating its downside to renew three-month lows in European trading on Tuesday. The ongoing escalation in the Iran war, combined with rising Oil prices, weighs negatively on the higher-yielding Pound Sterling as the US Dollar capitalizes on increased haven demand.

Gold bounces off lows, back above $5,100

Gold remains on the defensive, eroding part of the recent multi-day advance and managing to trade back above the $5,100 mark per troy ounce on Tuesday. The precious metal initially dropped just below the critical $5,000 threshold on the back of the persistent strength of the Greenback, higher US Treasury yields across the curve and investors' repricing of Fed rate cuts.